Active MPN Research
With many clinical trials in progress, as well as clinicians and laboratory scientists around the world researching MPNs, our understanding of these diseases continues to grow. New research on the causes and treatment of MPNs is constantly being published. Here you can find links to the latest MPN research publications.
- Environmental Toxins Found Historically in the Polycythemia Vera Cluster Area and their Potential for Inducing DNA Damage
- Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function
- Current Management of Chronic Neutrophilic Leukemia
- New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome
- Functional Consequences of Mutations in Myeloproliferative Neoplasms
- Environmental Toxins Found Historically in the Polycythemia Vera Cluster Area and their Potential for Inducing DNA Damage
- Complete resolution of a cutaneous grade 2 graft-versus-host disease after liver transplantation using ruxolitinib
- Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Complete resolution of a cutaneous grade 2 graft-versus-host disease after liver transplantation using ruxolitinib
- Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Complete resolution of a cutaneous grade 2 graft-versus-host disease after liver transplantation using ruxolitinib
- Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study